Pudil J, Batko S, Menclová K, Bláha M, Ryska M
Rozhl Chir. 2015 Dec;94(12):522-5.
Liver metastases are diagnosed in 60% of patients with colorectal cancer, both at the time of diagnosis or later in the course of their management. Surgical treatment is the sole potentially curable method with 5-year overall survival of approximately 50%. However, only less than 20% of patients underwent liver resection. A joint effort of medical oncologists and surgeons is to increase the numbers of resected patients. The "liver first approach" (LFA) is one of approaches aimed at increasing resecability. The authors present their preliminary results using this method.
102 patients were included in the multicentre study supported by the grant IGA NT 13660 Evaluation of quality of multimodal treatment for patients with colorectal cancer liver metastases - conducted at the Central Military Hospital between September 2012 and January 2015. We used LFA in 12 patients (12%). Patients were indicated for liver resection based on good response to neoadjuvant systemic therapy. Multiple bilobar liver involvement (>4 metastases) was present in 11 cases and one large solitary metastasis in the right liver lobe in one case. The primary tumor was located in the rectum in 9 patients, in the rectosigmoid in 3 patients; 3 patients had a colostomy. Others showed no signs of bowel obstruction.
We have performed R0 resections in 11 cases, and two-stage hepatectomy with portal vein embolisation was indicated 3 times (in one case we did not finish the second stage due to quick progression after PVE). We performed major resections 7 times, along with sever extraanatomic resections, incl. 11 RFA (6 times in combination with major resections). Perioperative mortality was 0%, morbidity 33% (Dindo-Clavien >2). Ten patients underwent adjuvant chemotherapy, in 7 cases including radiotherapy of the small pelvis due to a local advanced primary tumor. Resection of the primary tumor was done in 7 patients (58%). Two patients died recently because of disease progression (17%); progression was observed in 6 patients (50%).
We deem the LFA suitable especially for patients with metastatic rectal tumors where adjuvant systemic therapy can be combined with radiotherapy. The timing of the resection of the primary tumor still remains a question: it is necessary to rule out potential recurrence of liver metastases, which affected more than 50% of the patients. The benefit of LFA must be confimed by randomised studies.
60%的结直肠癌患者在诊断时或治疗过程中的后期被诊断出肝转移。手术治疗是唯一有可能治愈的方法,5年总生存率约为50%。然而,只有不到20%的患者接受了肝切除术。肿瘤内科医生和外科医生共同努力以增加接受手术切除的患者数量。“肝优先 approach”(LFA)是旨在提高可切除性的方法之一。作者展示了使用该方法的初步结果。
102例患者纳入了由IGA NT 13660资助的多中心研究——结直肠癌肝转移患者多模式治疗质量评估,该研究于2012年9月至2015年1月在中央军事医院进行。我们对12例患者(12%)使用了LFA。根据对新辅助全身治疗的良好反应,患者被确定适合进行肝切除术。11例患者存在多叶肝脏受累(>4个转移灶),1例患者右肝叶有一个大的孤立转移灶。9例患者的原发肿瘤位于直肠,3例位于直肠乙状结肠交界处;3例患者有结肠造口术。其他患者无肠梗阻迹象。
我们对11例患者进行了R0切除,3次进行了门静脉栓塞的二期肝切除术(1例患者在门静脉栓塞后因疾病快速进展未完成第二阶段手术)。我们进行了7次大手术,以及多次非解剖性大手术,包括11次射频消融(6次与大手术联合)。围手术期死亡率为0%,发病率为33%(Dindo-Clavien分级>2级)。10例患者接受了辅助化疗,7例患者因局部晚期原发肿瘤接受了盆腔放疗。7例患者(58%)切除了原发肿瘤。2例患者最近因疾病进展死亡(17%);6例患者(50%)出现疾病进展。
我们认为LFA特别适用于转移性直肠肿瘤患者,其中辅助全身治疗可与放疗联合。原发肿瘤切除的时机仍然是一个问题:有必要排除肝转移的潜在复发,超过50%的患者受到了影响。LFA的益处必须通过随机研究来证实。